Paragon Biosciences LLC, the Chicago-based life science innovator that invests in, builds, and advises bioscience companies, is announcing the launch of its seventh portfolio company, Qlarity Imaging LLC, which was founded to harness the value of artificial intelligence (AI) to improve medical outcomes.
Paragon Biosciences, LLC Chairman and CEO Jeff Aronin was recently recognized by the Northern Illinois University (NIU) College of Business as the 2019 recipient of their Innovation and Entrepreneurship Award.
The newly-created position is the result of rapid expansion at Paragon and its portfolio companies, which are developing novel medical treatments.
With its highest honor, a Gold level award, Best in Biz recognizes Jeff Aronin for his lifelong commitment to developing breakthrough therapies for severe medical conditions.
Paragon Biosciences CEO Jeff Aronin spoke with Crain’s Chicago Business on his role in the company, his vision for Paragon, and his mission to bring treatments to patients suffering from rare, genetic, debilitating diseases that too few companies focus on.
Paragon Biosciences (Paragon) today announced the completion of a new capital investment of $71.8 million for Castle Creek Pharma (Castle Creek), a Paragon portfolio company.
Paragon Biosciences CEO Jeff Aronin was recognized this week by Insights Care magazine for his innovative leadership in the biosciences sector and for his work bringing life-altering drugs to patients in need.
Harmony Biosciences, LLC (Harmony), a portfolio company of Paragon Biosciences (Paragon), was joined by Pennsylvania Governor Tom Wolf to announce the opening of its completed, 15,651 square-foot headquarters located in Plymouth Meeting, PA.
Paragon Biosciences (Paragon) today announced Skyline Biosciences (Skyline) as the newest addition to its growing portfolio of drug-development companies. Paragon identifies unmet patient needs, invests in the development of novel medicines, and incubates biopharmaceutical companies, such as Skyline.
Biopharmaceutical company Emalex Biosciences (Emalex), the newest member of the Paragon Biosciences (Paragon) portfolio of companies, today announced it acquired Psyadon Pharmaceuticals and the exclusive rights to develop, register and market ecopipam, a new chemical entity with orphan drug designation for the treatment of pediatric Tourette Syndrome (TS) in patients under 16 years of age.
Sign up with your email address to receive news and updates.
We respect your privacy.